罕见癌症随机临床试验策略。
Strategy for randomised clinical trials in rare cancers.
作者信息
Tan Say-Beng, Dear Keith B G, Bruzzi Paolo, Machin David
机构信息
Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, 11 Hospital Drive, Singapore 169610.
出版信息
BMJ. 2003 Jul 5;327(7405):47-9. doi: 10.1136/bmj.327.7405.47.
Abstract
Proving that a new treatment is more effective than current treatment can be difficult for rare conditions. Data from small randomised trials could, however, be made more robust by taking other related research into account
摘要
对于罕见病而言，证明一种新疗法比现有疗法更有效可能很困难。然而，通过考虑其他相关研究，来自小型随机试验的数据可以变得更可靠。
相似文献
1
Strategy for randomised clinical trials in rare cancers.
BMJ. 2003 Jul 5;327(7405):47-9. doi: 10.1136/bmj.327.7405.47.
2
Do we need randomised trials for rare cancers?
Eur J Cancer. 2015 Jul;51(11):1355-7. doi: 10.1016/j.ejca.2015.04.015. Epub 2015 May 8.
3
Clinical trials and rare diseases.
N Engl J Med. 2003 Jun 12;348(24):2455-6. doi: 10.1056/NEJMe030024.
4
Randomised controlled trials in oncology closed early for benefit: trends in methodology, results, and interpretation.
Eur J Cancer. 2011 Apr;47(6):854-63. doi: 10.1016/j.ejca.2010.12.005. Epub 2011 Feb 4.
5
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.
Eur J Cancer. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24.
6
[Purposefulness of using fuzzy logic approaches in the rare disease clinical trials].
Georgian Med News. 2011 Apr(193):22-4.
7
International rare cancers initiative.
Lancet Oncol. 2013 Feb;14(2):109-10. doi: 10.1016/S1470-2045(12)70570-3.
8
Randomised controlled trials (RCTs)--essentials.
Singapore Med J. 2003 Feb;44(2):60-3.
9
Can external and subjective information ever be used to reduce the size of randomised controlled trials?
Contemp Clin Trials. 2008 Mar;29(2):211-9. doi: 10.1016/j.cct.2007.07.009. Epub 2007 Aug 2.
10
The dangers of subgroup analysis.
Lancet Oncol. 2001 Jan;2(1):9. doi: 10.1016/S1470-2045(00)00186-8.
引用本文的文献
1
Empowering pediatric, adolescent, and young adult patients with cancer utilizing generative AI chatbots to reduce psychological burden and enhance treatment engagement: a pilot study.
Front Digit Health. 2025 Feb 25;7:1543543. doi: 10.3389/fdgth.2025.1543543. eCollection 2025.
2
An Evaluation of Rare Cancer Policies in Europe: A Survey Among Healthcare Providers.
Cancers (Basel). 2025 Jan 7;17(2):164. doi: 10.3390/cancers17020164.
3
Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.
Cancers (Basel). 2024 Apr 12;16(8):1489. doi: 10.3390/cancers16081489.
4
Improving the efficiency of clinical trials in multiple sclerosis.
Mult Scler. 2023 Aug;29(9):1136-1148. doi: 10.1177/13524585231189671.
5
Descriptive Epidemiology of Hospitalization of Patients with a Rare Tumor in an Italian Region.
Curr Oncol. 2022 Dec 8;29(12):9711-9721. doi: 10.3390/curroncol29120762.
6
Association between circulating vitamin E and ten common cancers: evidence from large-scale Mendelian randomization analysis and a longitudinal cohort study.
BMC Med. 2022 May 11;20(1):168. doi: 10.1186/s12916-022-02366-5.
7
Descriptive epidemiological study of rare, less common and common cancers in Western Australia.
BMC Cancer. 2021 Jul 8;21(1):779. doi: 10.1186/s12885-021-08501-4.
8
Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers.
Front Oncol. 2021 Mar 8;11:636561. doi: 10.3389/fonc.2021.636561. eCollection 2021.
9
Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
BMC Med Res Methodol. 2019 Apr 24;19(1):85. doi: 10.1186/s12874-019-0714-z.
10
Emerging Opportunities for Target Discovery in Rare Cancers.
Cell Chem Biol. 2017 Sep 21;24(9):1075-1091. doi: 10.1016/j.chembiol.2017.08.002.
本文引用的文献
1
Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma.
Control Clin Trials. 2003 Apr;24(2):110-21. doi: 10.1016/s0197-2456(02)00318-5.
2
Following a trial that stopped early: what next for adjuvant hepatic intra-arterial iodine-131 lipiodol in resectable hepatocellular carcinoma?
J Clin Oncol. 2002 Mar 15;20(6):1709. doi: 10.1200/JCO.2002.20.6.1709.
3
Underpowered studies.
Br J Surg. 2002 Feb;89(2):129-31. doi: 10.1046/j.0007-1323.2001.01989.x.
4
Monitoring of large randomised clinical trials: a new approach with Bayesian methods.
Lancet. 2001 Aug 4;358(9279):375-81. doi: 10.1016/S0140-6736(01)05558-1.
5
Methods in health service research. An introduction to bayesian methods in health technology assessment.
BMJ. 1999 Aug 21;319(7208):508-12. doi: 10.1136/bmj.319.7208.508.
6
Why "underpowered" trials are not necessarily unethical.
Lancet. 1997 Sep 13;350(9080):804-7. doi: 10.1016/s0140-6736(97)02290-3.
7
Surrogate end points in clinical trials: are we being misled?
Ann Intern Med. 1996 Oct 1;125(7):605-13. doi: 10.7326/0003-4819-125-7-199610010-00011.
8
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
Control Clin Trials. 1996 Feb;17(1):1-12. doi: 10.1016/0197-2456(95)00134-4.
9
Clinical trials and rare diseases: a way out of a conundrum.
BMJ. 1995 Dec 16;311(7020):1621-5. doi: 10.1136/bmj.311.7020.1621.
10
Over-the-counter cold medications. A critical review of clinical trials between 1950 and 1991.
JAMA. 1993 May 5;269(17):2258-63. doi: 10.1001/jama.269.17.2258.
Zotero 插件